Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample
Autore:
Hamilton, SH; Edgell, ET; Revicki, DA; Breier, A;
Indirizzi:
MEDTAP Int, Ctr Hlth Outcomes Res, Bethesda, MD USA MEDTAP Int Bethesda MD USA Int, Ctr Hlth Outcomes Res, Bethesda, MD USA Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA Eli Lilly & CoIndianapolis IN USA 46285 Labs, Indianapolis, IN 46285 USA
Titolo Testata:
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
fascicolo: 5, volume: 15, anno: 2000,
pagine: 245 - 255
SICI:
0268-1315(200009)15:5<245:FOISAC>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
QUALITY-OF-LIFE; RANDOMIZED CLINICAL-TRIAL; NEGATIVE SYMPTOMS; PSYCHOTIC DISORDERS; CLOZAPINE; PLACEBO;
Keywords:
antipsychotics; Europe; hospitalization; olanzapine; outcomes; reintegration; schizophrenia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
43
Recensione:
Indirizzi per estratti:
Indirizzo: Edgell, ET Eli Lilly & Co, Lilly Res Ctr, Lilly Res Labs, Erl Wood Manor, Windlesham GU20 6PH, Surrey, England Eli Lilly & Co Erl Wood Manor Windlesham Surrey England GU20 6PH
Citazione:
S.H. Hamilton et al., "Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample", INT CLIN PS, 15(5), 2000, pp. 245-255

Abstract

The primary aim of this study was to compare functional outcomes between patients with schizophrenia treated with olanzapine or haloperidol in Europe. The sample consisted of European patients from a large, international, double-blind, randomized clinical trial. Patients were randomized to receive either olanzapine (n = 520) or haloperidol (n = 258) for a 6-week acute phase followed by a 46-week maintenance phase for responders. Olanzapine-treated patients experienced superior improvements compared to haloperidol-treated patients on all efficacy measures assessed in both phases. A greater percentage of olanzapine-treated patients had greater than or equal to 20% improvement in the Quality of Life Scale total score during both the acute (50.0% versus 31.0%, P = 0.071) and maintenance (69.5% versus 41.7%, P = 0.006) phases compared to haloperidol-treated patients. For patients who enteredthe maintenance phase as outpatients, olanzapine-treated patients were significantly less likely to require subsequent hospitalization compared to haloperidol-treated patients (P = 0.001). A significantly greater percentage of the olanzapine group compared to the haloperidol group worked part-time or full-time (15.1% versus 5.3%, P = 0.018), participated in useful work greater than or equal to 75% of the time (21.0% versus 10.5%, P = 0.038), andsocialized more than once a month (53.8% versus 37.9%, P = 0.004) during the maintenance phase. The findings from this study suggest that olanzapine's clinical profile leads to reduced hospitalization and improvements in work and social functioning superior to that achieved with haloperidol treatment. (C) 2000 Lippincott williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/03/20 alle ore 12:29:53